Showing results (421-430 of 486) with videos related to
Sort By:
Pageof 49
Cancer Science|November 17, 2024
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinomaKanami Mori, Kazuyuki Numakura, Yuto Matsushita, et al.Scientific Reports|November 25, 2025
Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancerManato Kanesaka, Tomokazu Sazuka, Yuki Kita, et al.European Urology|January 22, 2026
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 TrialHiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al.Nature Communications|November 21, 2020
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancersKeito Okazaki, Hayato Anzawa, Zun Liu, et al.Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.World Journal of Urology|September 26, 2024
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapyKazutoshi Fujita, Yuto Matsushita, Shingo Toyoda, et al.Journal of Clinical Pathology|May 8, 2020
Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomasMitsuko Furuya, Yasuhiro Iribe, Yoji Nagashima, et al.International Journal of Clinical Oncology|March 27, 2015
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancerMasahiro Nozawa, Hirofumi Mukai, Shunji Takahashi, et al.Cancer Medicine|September 23, 2020
Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancerKohei Hashimoto, Yasuhide Miyoshi, Tetsuya Shindo, et al.Japanese Journal of Clinical Oncology|February 2, 2025
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective studyHiroshi Kikuchi, Takahiro Osawa, Yuto Matsushita, et al.Pageof 49